Humanitas Research Hospital attend ASH 2024 in representation of GenoMed4All
For another consecutive year, GenoMed4All was present at the ASH meeting in San Diego, thanks to the participation of investigators from Humanitas Research Hospital.
The 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in California on 7-10 December 2024, showcased the latest research and developments in hematology, serving as a pivotal gathering for hematology professionals from across the globe.
Also in representation of our sister project SYNTEHMA, our shared consortium partner Humanitas Research Hospital presented 6 abstracts that highlighted the transformative potential of artificial intelligence in advancing personalized and precision medicine for hematological diseases.
Through five poster presentations and one conference talk, the Humanitas team, led by Matteo Della Porta, unveiled the work they’ve been developed in the last year:
- ‘Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patients with Myeloid Neoplasms’ by Gianluca Asti
- ‘An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative by GenoMed4All and SYNTHEMA Consortia’ by Gianluca Asti
- ‘A Comprehensive, Artificial Intelligence-Based, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology’ by Saverio D’Amico
- ‘Generation of Multimodal Longitudinal Synthetic Data by Artificial Intelligence to Improve Personalized Medicine in Hematology’ by Saverio D’Amico
- ‘Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach’ by Elisabetta Sauta
The active participation of GenoMed4All and SYNTHEMA at ASH 2024 underscored their commitment to integrating AI into hematology to improve patient outcomes. Engaging with the global hematology community at such a high-profile event facilitated the dissemination of their innovative research findings, fostering discussions on the practical applications of AI in clinical settings.
GenoMed4All at EHA 2024: Reinforcing our commitment to advance innovation in hematology
The European Hematology Association (EHA) Annual Congress is one of the most significant events in the field of hematology, bringing together experts, researchers and industry leaders from around the world.
The 3rd edition of the conference took place in Madrid, on 13-16 June 2024, to provide a closer look at the latest advancements in hematology, particularly around research, treatments and policy. This year’s theme focused on fostering innovation and collaboration to improve patient outcomes, emphasizing the role of cutting-edge technologies in shaping the future of hematology.
As part of this prestigious event, partners of GenoMed4All and sister project SYNTHEMA participated in a dedicated session organized by ERN-EuroBloodNet, titled ‘Data driven research & Innovative therapies’. María del Mar Mañú Pereira, Head of Rare Anemia Disorders Laboratory at Vall d’Hebron Institute of Research (VHIR), and Raffaella Colombatti, Pediatric Hematologist and Associate Professor at University of Padova, presented the core objectives of both EU-funded initiatives, with a particular focus on the work carried out for the Sickle Cell Disease case study.
Other GenoMed4All representatives also attended EHA 2024 in Madrid to help disseminate the project’s mission and engage with the broader hematology community, including: Federico Álvarez from Universidad Politecnica de Madrid, Matteo Della Porta from Humanitas Research Hospital, and Diana López from AUSTRALO.
Being present at such a high-profile event is crucial for increasing awareness about our work, and contributing to discussions on the latest scientific and technological developments in the field. Beyond the scientific discourse, EHA 2024 reaffirmed the importance of collective efforts in driving innovation and improving patient care, reinforcing GenoMed4All’s commitment to advancing hematological research through technology-driven solutions.
ERN-EuroBloodNet and GenoMed4All at #ASH21
The strong 63rd Annual Meeting and Exposition of the American Society of Hematology took place this past week in Atlanta... and our colleagues from ERN-EuroBloodNet did not miss the occasion! The results from two projects promoted by the ERN were showcased in the oral and poster abstracts on December 13th, you can browse through their abstracts here.
We are already looking forward to next year's event!
#SCD is a disease on Focus in #EuroBloodNet and is addressed in projects such as @genomed4all where the #ERN is involved! Yesterday two #EuroBloodNetExperts involved in this disease were present at #ASH21! #EuroBloodNetinASH2021 #ERNeu @Pablo_Velasco_P @ejvanbeers pic.twitter.com/n0lfdyBSfj
— ERN EuroBloodNet (@ERNEuroBloodNet) December 14, 2021
